NextCure, Inc. (NXTC)
| Previous Close | 4.7000 |
| Open | 4.6700 |
| Bid | 4.4900 x 1000 |
| Ask | 4.7700 x 1100 |
| Day's Range | 4.4800 - 4.7500 |
| 52 Week Range | 3.2500 - 9.1800 |
| Volume | |
| Avg. Volume | 174,132 |
| Market Cap | 124.862M |
| Beta (5Y Monthly) | 0.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6570 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.08 |
- GlobeNewswire
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM
BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, presented in vivo data at the 2022 ECM Pharmacology Congress in Copenhagen that demonstrated NC410 remodels tumor ECM, enhances immune cell infiltration, alleviates immunosuppression, and reduces tumor growth in a humanized mouse tumor model. The
- Simply Wall St.
We're Hopeful That NextCure (NASDAQ:NXTC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GlobeNewswire
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting
BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that collaborator Brahm Segal, M.D., of Roswell Park Comprehensive Cancer Center shared nonclinical data from a research study that models the ability of NC410 to block neutrophil-mediated suppression of T cells in a tumor microen
